Ribupatide reports positive Phase 3 diabetes results in China
KEY STEPHengrui reported positive topline results from a Phase 3 study of ribupatide in adults with type 2 diabetes inadequately controlled with oral therapy. Both doses met the primary objective versus semaglutide 1 mg, and the 4 mg dose showed statistically superior HbA1c reduction. The company said it planned a Chinese marketing application.
Roadmap reference